Relation between contractile reserve and improvement in left ventricular function with Beta-blocker therapy in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

被引:47
作者
Seghatol, FF
Shah, DJ
Diluzio, S
Bello, D
Johnson, MR
Cotts, WG
O'Donohue, JA
Bonow, RO
Gheorghiade, M
Rigolin, VH
机构
[1] Northwestern Med Fac Fdn, Chicago, IL 60611 USA
[2] Northwestern Univ, Feinberg Sch Med, Div Cardiol, Dept Med, Evanston, IL 60208 USA
[3] Chicago VA Hlth Care Syst, Lakeside Div, Chicago, IL USA
关键词
D O I
10.1016/j.amjcard.2003.12.023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Beta blockers improve left ventricular (LV) ejection fraction but patient responses are heterogenous. We investigated the role of contractile reserve (CR) in predicting beta-blocker response in ischemic and nonischemic cardiomyopathy. Resting and low-dose dobutamine echocardiograms were recorded in 32 patients with heart failure (LV ejection fraction less than or equal to 35%), 18 with ischemic cardiomyapathy (IC) and 14 with idiopathic dilated cardiomyopathy (IDC). A segment was defined as CR positive (CR+) or negative (CR-) biased on response to dobutamine. Patients were then classified as CR+ or CR- based on number of improved segments (IC group) or ejection fraction improvement (IDC group) in response to dobutamine. During follow-up (2, 6, and 14 months after beta-blocker initiation), response was measured by the percent of segments showing improved contractility from baseline, ejection fraction, and wall motion score index. In the IC group, the percent of improved segments was greater at 2 and 6 months in CR+ versus CR- (70% vs 15% and 39% vs 17%, p < 0.05), whereas it was greater at all periods in the patients with IDC (36% vs 9% at 2 months, 50% vs 19% at 6 months, and 63% vs 42% at 14 months, p < 0.05). Findings for ejection fraction and wall motion score index were similar. Therefore, time course and magnitude of improvement in IV function in patients with heart failure receiving beta blockers are related to CR status. CR predicts a greater early response in IC, whereas it predicts a greater response at all time periods in IDC. However, even patients without CR showed improvement in LV function at 14 months. (C) 2004 by Excerpta Medica, Inc.
引用
收藏
页码:854 / 859
页数:6
相关论文
共 20 条
[1]   DOBUTAMINE ECHOCARDIOGRAPHY IN MYOCARDIAL HIBERNATION - OPTIMAL DOSE AND ACCURACY IN PREDICTING RECOVERY OF VENTRICULAR-FUNCTION AFTER CORONARY ANGIOPLASTY [J].
AFRIDI, I ;
KLEIMAN, NS ;
RAIZNER, AE ;
ZOGHBI, WA .
CIRCULATION, 1995, 91 (03) :663-670
[2]   LOW-DOSE DOBUTAMINE IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION IDENTIFIES VIABLE BUT NOT CONTRACTILE MYOCARDIUM AND PREDICTS THE MAGNITUDE OF IMPROVEMENT IN WALL MOTION ABNORMALITIES IN RESPONSE TO CORONARY REVASCULARIZATION [J].
BARILLA, F ;
GHEORGHIADE, M ;
ALAM, M ;
KHAJA, F ;
GOLDSTEIN, S .
AMERICAN HEART JOURNAL, 1991, 122 (06) :1522-1531
[3]   Assessment of myocardial viability by dobutamine echocardiography, positron emission tomography and thallium-201 SPECT - Correlation with histopathology in explanted hearts [J].
Baumgartner, H ;
Porenta, G ;
Lau, YK ;
Wutte, M ;
Klaar, U ;
Mehrabi, M ;
Siegel, RJ ;
Czernin, J ;
Laufer, G ;
Sochor, H ;
Schelbert, H ;
Fishbein, MC ;
Maurer, G .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (06) :1701-1708
[4]   Identification of viable myocardium [J].
Bonow, RO .
CIRCULATION, 1996, 94 (11) :2674-2680
[5]   Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure [J].
Bristow, MR ;
Gilbert, EM ;
Abraham, WT ;
Adams, KF ;
Fowler, MB ;
Hershberger, RE ;
Kubo, SH ;
Narahara, KA ;
Ingersoll, H ;
Krueger, S ;
Young, S ;
Shusterman, N .
CIRCULATION, 1996, 94 (11) :2807-2816
[6]   Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial [J].
Cleland, JGF ;
Pennell, DJ ;
Ray, SG ;
Coats, AJ ;
Macfarlane, PW ;
Murray, GD ;
Mule, JD ;
Vered, Z ;
Lahiri, A .
LANCET, 2003, 362 (9377) :14-21
[7]   Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure [J].
Colucci, WS ;
Packer, M ;
Bristow, MR ;
Gilbert, EM ;
Cohn, JN ;
Fowler, MB ;
Krueger, SK ;
Hershberger, R ;
Uretsky, BF ;
Bowers, JA ;
SacknerBernstein, JD ;
Young, ST ;
Holcslaw, TL ;
Lukas, MA .
CIRCULATION, 1996, 94 (11) :2800-2806
[8]  
FEIGENBAUM H, 1994, ECHOCARDIOGR-J CARD, P137
[9]   Chronic heart failure in the United States - A manifestation of coronary artery disease [J].
Gheorghiade, M ;
Bonow, RO .
CIRCULATION, 1998, 97 (03) :282-289
[10]  
Hjalmarson Å, 1999, LANCET, V353, P2001